Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 19

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 19
---
 Shares issuable upon the exercise of stock options in connection with the acquisition of DARA Bioscience, Inc. at a weighted 
 average exercise price of $981.91 per share;                                                                                            |

| · | warrants, including pre-funded warrants, exercisable for 488,720 Depositary Shares (representing 4,887,200,000 Ordinary Shares), 
 at a weighted average exercise price of $43.37 per Depositary Share; and                                                         |

| · | any warrants issuable in this offering. |

| 13 |

<div align='center'>RISK FACTORS</div>

Investing in our securities involves a high degree of risk. You should carefully consider the risks described under “Risk Factors” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, as filed with the SEC, and all other information contained in, or incorporated by reference in, this prospectus, as updated by those subsequent filings with the SEC under the Exchange Act, before making an investment decision. The risks and uncertainties described below and incorporated by reference are not the only ones we face. Additional risks and uncertainties not presently known to us may also adversely affect our business. Our business, financial condition and/or results of operations could be materially and adversely affected if any of these risks occur, and as a result the trading price of the Depositary Shares could decline and you could lose all or part of your investment.

This prospectus also contains forward-looking statements that involve risks and uncertainties. See “Special Note Regarding Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors.

Risks Related to This Offering

We are selling a substantial number of Depositary Shares in this offering, which could cause the price of our Depositary Shares to decline.

In this offering, we are offering up to an aggregate of 4,422,604 Depositary Shares, Pre-Funded Warrants to purchase up to 4,422,604 Depositary Shares, Series L Warrants exercisable for up to 8,845,208 Depositary Shares. We are registering 1,348,894,200,000Ordinary Shares (in the form of Depositary Shares) under this prospectus.

Furthermore, the market price of our Depositary Sharescould decline as a result of actual or anticipated future issuances, including the issuance of shares from Series L Warrant
exercises, which will result in substantial dilution to existing shareholders